Safety and Efficacy of Pivot‐Bridge for Severe Functional Tricuspid Regurgitation: The First‐in‐Human Experiences
Catheterization and Cardiovascular Interventions · 2026-05 · 107 (6) · 2069-2077
DOI: 10.1002/ccd.70572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 27.03.2026. Verfasst von Eun Kyoung Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea. Hauptthemen laut MEDLINE: Tricuspid Valve Insufficiency, Cardiac Catheterization, Tricuspid Valve, Heart Valve Prosthesis Implantation. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Korea Medical Device Development Fund grant funded by the Korea government, Ministry of Science and Information and Communication Technologies, Ministry of Trade, Industry and Energy, Ministry of Health and Welfare.
Abstract (Originalsprache)
Background
The management of severe tricuspid regurgitation (TR) remains challenging. Although several promising transcatheter devices have been developed, procedural complexity and the need for special imaging techniques are hurdles to their widespread clinical application.
Aims
The study aimed to evaluate the safety and efficacy of a novel atraumatic vertical spacer, Pivot‐Bridge, for severe TR.
Methods
Patients with severe TR who were considered surgical candidates were enrolled. All procedures were guided by fluoroscopy and transthoracic echocardiography (TTE). Baseline characteristics, serious adverse events, and functional status were collected. TTE and cardiac computed tomography (CT) were serially performed for evaluation of TR and right ventricular (RV) remodeling.
Results
Fifteen patients (68 ± 11 years old, 27% women) were enrolled. Procedural success was achieved in all patients (the mean procedural time of 47 ± 24 min). During the device implantation (median 5 days), no serious adverse events occurred. TR was reduced by one grade or more in all patients. In TTE, vena contracta width and effective regurgitant orifice area significantly decreased by Pivot‐Bridge (1.6 ± 0.8 to 0.8 ± 0.3 mm; p < 0.001 and 1.2 ± 0.5 to 0.6 ± 0.3 cm 2 ; p < 0.001). RV end diastolic volume also significantly reduced at follow‐up CT (320.2 ± 93.7 to 294.4 ± 81.1 mm 3 ; p = 0.026). Ten patients underwent surgery with removal of the device, and five patients were stabilized by medical treatment, in whom the Pivot‐Bridge was removed percutaneously.
Conclusions
The Pivot‐Bridge was safe and effective in patients with severe TR. TR reduction was observed in all patients without periprocedural complications or adverse cardiovascular events during device placement. Registration ClinicalTrials.gov number: NCT05854095.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
- Department of Cardiology, School of Medicine, Pusan National University and Cardiovascular Center, Yangsan Hospital, Yangsan, South Korea.
- Department of Internal Medicine, Division of Cardiology, Hallym University Sacred Heart Hospital, Anyang, South Korea.
- Department of Internal Medicine, SoonChunHyang University College of Medicine, SoonChunHyang University Bucheon Hospital, Bucheon, South Korea.
- Department of Cardiology in Internal Medicine, Chungnam National University Hospital, School of Medicine, Chungnam National University, Daejeon, South Korea.
- Department of Cardiology, Sejong General Hospital, Bucheon, South Korea.
ORCID-Profile: Min-Ku Chon, Yong-Hyun Park, Eun Seok Shin
Förderung
- Korea Medical Device Development Fund grant funded by the Korea government
- Ministry of Science and Information and Communication Technologies
- Ministry of Trade, Industry and Energy, Ministry of Health and Welfare
- Ministry of Food and Drug Safety
- Tau Medical provided the Pivot-TR devices
Zitieren
APA
Kim, E. K., Chon, M. K., Kim, H. S., Park, Y. H., Suh, J., Park, J. H., Lee, J. H., Choi, Y. J., Shin, E. S., Yoon, H. J., Yang, D. H., Park, J., Lee, S. W., & Hahn, J. Y. (2026). Safety and Efficacy of Pivot‐Bridge for Severe Functional Tricuspid Regurgitation: The First‐in‐Human Experiences. Catheterization and Cardiovascular Interventions, 107(6), 2069-2077. https://doi.org/10.1002/ccd.70572
Vancouver
Kim EK, Chon MK, Kim HS, Park YH, Suh J, Park JH, et al. Safety and Efficacy of Pivot‐Bridge for Severe Functional Tricuspid Regurgitation: The First‐in‐Human Experiences. Catheterization and Cardiovascular Interventions. 2026;107(6):2069-2077. doi:10.1002/ccd.70572
BibTeX
@article{Kim2026,
author = {Kim, Eun Kyoung and Chon, Min-Ku and Kim, Hyun-Sook and Park, Yong-Hyun and Suh, Jon and Park, Jae-Hyeong and Lee, Jae-Hwan and Choi, Young Jin and Shin, Eun Seok and Yoon, Hyuck-Jun and Yang, Dong Hyun and Park, Junhui and Lee, Seung-Whan and Hahn, Joo-Yong},
title = {Safety and Efficacy of Pivot‐Bridge for Severe Functional Tricuspid Regurgitation: The First‐in‐Human Experiences},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {107},
number = {6},
pages = {2069--2077},
doi = {10.1002/ccd.70572}
}
EUVIMED